The Brand Name KLOTBUSTER Has Generic Salt :: Streptokinase 

KLOTBUSTER  Is From Company Alembic Priced :: Rs. 1395

KLOTBUSTER have Streptokinase is comes under Sub class Thrombolytics of  Main Class Hematological System

Main Medicine Class:: Hematological System  Sub Medicine Class :: Thrombolytics 

 Salt Name :  OR Generic Name Form Price : MRP /Probable Packing
Streptokinase  INJ  Rs. 1395  VIAL
Brand Name Company / Manufacturers Strength Unit Price / VIAL
 KLOTBUSTER  Alembic  7,50,000IU.  VIAL Rs. 1395

Company  Brand Name  Salt Combination Main Medical Class Sub Medical Class
 From Alembic :: KLOTBUSTER  Streptokinase  Hematological System Thrombolytics

Indications for Drugs ::

Acute Evolving Myocardial Infarction, Acute Massive Pulmonary Embolism, Deep Vein Thrombosis, Arterial Thrombosis or Embolism, Arteriovenous Cannulae Occlusion.

Drug Dose ::

Adult: IV infusion: Acute MI: 1.5 million u as a single dose immediately after onset of symptoms. Total solution volume 45 ml. Infusion rate: Infuse 45 ml within 60 mins. Pulmonary thromboembolism; Deep Vein Thrombosis, Arteriovenous occlusions Loading dose: 250,000 u via infusion. Total solution volume 90 ml, Infusion rate: Infuse 30 ml/hour for 30 min. Maintenance: 100,000 u/hr for 24-72 hr depending on the condition treated. Duration for cerebral retinal thrombosis: 12 hr. Maintain thrombin clotting time at 2-4 times normal values. Child: Loading dose: 2500-4000 units/kg over 30 min, followed by infusion of 500-1000 units/kg/hr, continued until reperfusion occurs, up to 3 days. Initial dose may be estimated by streptokinase resistance test. Monitor treatment by maintaining thrombin clotting time at 2-4 times normal values.

Contraindication ::

Severe hypertension, recent stroke, cerebral neoplasm, recent history of peptic ulcer disease, ulcerative colitis, pancreatitis, subacute bacterial endocarditis, coagulation defects also due to liver or kidney disease, recent surgery, childbirth. Hypersensitivity, increased risk of cerebral bleeding, trauma. Pregnancy. Active internal bleeding, bleeding GI lesions. Arteriovenous malformation or aneurysm; recent (within 10 days) facial or head trauma, intracranial or intraspinal surgery, More than 5 days and less than 12 months since previous Streptokinase therapy.

Drug Precautions ::

Mitral stenosis associated with AF. Streptokinase treatment within last 12 mth, use after prolonged or traumatic CPR; diabetic retinopathy. Elderly. Because of the increased likelihood of resistance, due to antistreptokinase antibodies, retreatment with Streptokinase or Streptokinase-containing products may not be effective if administered between five days and twelve months of prior Streptokinase administration or Streptococcal infections, such as Streptococcal pharyngitis, acute rheumatic fever or acute glomerulonephritis secondary to a Streptococcal infection. In principle, no thrombolytic treatment should be commenced before the 10th postoperative day. However, in cases of pulmonary embolism, the indication for earlier treatment may be very strong and after careful consideration of all the risks, Streptokinase may be given before the tenth postoperative day. The danger of bleeding from the operative area must, of course, be taken into account. The danger of haemorrhage is increased by simultaneous or previous treatment with anticoagulants (e.g., Heparin) or substances which inhibit platelet formation or function. If the patient is under active heparinisation, it should be neutralised by the administration of protamine sulphate before the start of thrombolytic therapy. Repeated Administration After administration of Streptokinase, the titre of antistreptokinase antibodies begins to rise after approximately one week, reaching a peak at 2 to 3 weeks and remains elevated for 8 to 12 months. Because of the increased likelihood of resistance, Streptokinase may not be effective if given during this period.

Drug Side Effects ::

Headache and back pain, muscle pain (including myalgia), chills and/or fever as well as asthenia/malaise. Gastrointestinal or genitourinary bleedings (including aggravation of menstrual bleeding), epistaxis. Development of antistreptokinase antibodies. Hypotension, heart rate and rhythm disorders, angina pectoris. Recurrent ischaemia, heart failure, reinfarction, cardiogenic shock, pericarditis, pulmonary oedema. Nausea, diarrhoea, epigastric pain and vomiting. Arrhythmia, bruising, rash, pruritus, acute renal failure due to embolism and haemorrhage. Cerebral, peripheral and pulmonary embolism. Allergic reactions, liver enzyme abnormalities, hypotension. Potentially Fatal: Haemorrhage; anaphylactic shock.

Pregnancy category ::
Pregnancy category

3

Drug Mode of Action ::  

Streptokinase forms a complex with plasminogen which then converts plasminogen to plasmin. Plasmin breaks down clots as well as fibrinogen and other plasma proteins.

Drug Interactions ::

Antagonistic effects with antifibrinolytic agents e.g. aminocaproic acid. Potentially Fatal: Anticoagulants, heparin, antiplatelet agents e.g. aspirin and dipyridamole affect platelet function increasing the risk of haemorrhage.

 

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.

DOWNLOAD OUR ANDROID APP

One of the 1st in India.High Quality Generic Medicine Portal Android Application for Online Oreder & Information.

For More Join Our Membership and Get Additional 25% off on Meds, also get MLM Benefits to get a permanent earning source.

Join Membership How to Search Medicine
Android App

We would like to keep you updated with special notifications.